Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida.

The live and archived webcast of the presentation will be accessible from the company’s website https://ir.structuretx.com/events-presentations/events. The replay of the webcast will be available for 90 days.

About Structure Therapeutics
Structure Therapeutics is a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative oral treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a scientifically-driven, GPCR-targeted pipeline, featuring two wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.

Contacts:

Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com

Media:
Dan Budwick
1AB
Dan@1abmedia.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  236.15
+2.27 (0.97%)
AAPL  285.99
+2.88 (1.02%)
AMD  218.08
-1.68 (-0.76%)
BAC  53.30
+0.06 (0.11%)
GOOG  315.29
+0.17 (0.05%)
META  641.82
+0.95 (0.15%)
MSFT  491.18
+4.44 (0.91%)
NVDA  181.12
+1.20 (0.67%)
ORCL  203.29
+2.35 (1.17%)
TSLA  425.57
-4.57 (-1.06%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.